← Back to all trials
Completed
NCT05907499
Decitabine for Poor Graft Function Post Allo-HSCT
Conditions: Poor Graft Function
Sex: All
Ages: 16 Years – 70 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 76
Sponsor: The First Affiliated Hospital of Soochow University
Location: The First Affiliated Hospital of Soochow University Suzhou Jiangsu
Summary
This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.
Eligibility Criteria
Inclusion Criteria:
1. Diagnosed as PGF at day 28 post-HSCT or later. PGF was defined as two or three cytopenias, absolute neutrophil count ≤ 1.5 × 109/L, platelet count ≤ 30 × 109/L, hemoglobin ≤ 85g/L, lasting for more than 2 consecutive weeks;
2. Full donor chimerism;
3. Primary disease in remission;
4. No severe GVHD and relapse;
5. ECOG: 0-2;
6. Expected survival longer than 1 month
Exclusion Criteria:
1. Allergic to decitabine;
2. Active infections;
3. Uncontrolled GVHD;
4. Severe organ dysfunction;
5. Relapse of underlying malignancies;
6. Graft failure;
7. Received decitabine or participated in other clinical trials within one month before screening.
Source: ClinicalTrials.gov (NCT05907499). StuddyBuddy aggregates publicly available trial information.